Difference between revisions of "Alectinib (Alecensa)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Kinase inhibitors" to "")
m
Line 18: Line 18:
 
==Also known as==
 
==Also known as==
 
*'''Code names:''' AF802, AF-802, CH5424802, RG7853, RO5424802, UNII-LIJ4CT1Z3Y
 
*'''Code names:''' AF802, AF-802, CH5424802, RG7853, RO5424802, UNII-LIJ4CT1Z3Y
*'''Brand name:''' Alecensa
+
*'''Brand names:''' Alecensa, Alecinix, Alecnib
  
 
==References==
 
==References==
Line 33: Line 33:
  
 
[[Category:FDA approved in 2015]]
 
[[Category:FDA approved in 2015]]
[[Category:FDA approved drugs]]
 

Revision as of 16:58, 4 January 2021

General information

Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK). Alectinib and its metabolite M4 inhibit ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, which results in decreased growth of tumor cells which have ALK fusions, amplifications, or activating mutations.[1][2][3][4]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code names: AF802, AF-802, CH5424802, RG7853, RO5424802, UNII-LIJ4CT1Z3Y
  • Brand names: Alecensa, Alecinix, Alecnib

References